Carolyn Magill leads Aetion’s efforts to provide biopharma companies the analytics and evidence needed to optimize clinical development, advance strategies for regulatory approval and engage with payers in value-based care. By leveraging data sources — electronic health records, medical claims and disease registries among them — Aetion attempts to more accurately assess the safety and value of medical products.

The Aetion Evidence Platform can undertake complex analyses to generate real-world evidence at scale, which allows pharma organizations to supplement expensive clinical trials, help determine new indications for drugs and optimize treatments. These organizations can also use the platform to demonstrate to payers and regulators which medications best serve specific populations.

Before Aetion, Magill was CEO of Remedy Partners, a provider of bundled payments software and services. And as EVP of payer strategy and operations at Evolent Health, she helped grow the company from 50 employees and $8 million in annual revenue to a public company with 1,000 employees and $150 million in revenue.